Published in J Infect Dis on January 31, 2012
A Prospective Cohort Study to Improve HCV Care in Dialysis Patients (MATCH-D) | NCT03791814
The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability. Transfus Med Rev (2012) 1.14
Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States. J Clin Microbiol (2013) 0.95
Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection. Hepatology (2013) 0.94
Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis (2015) 0.89
Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol (2015) 0.88
Extensive Genetic Diversity of HIV-1 in Incident and Prevalent Infections among Malaysian Blood Donors: Multiple Introductions of HIV-1 Genotypes from Highly Prevalent Countries. PLoS One (2016) 0.87
Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island. Infect Genet Evol (2014) 0.83
Recent population expansions of hepatitis B virus in the United States. J Virol (2014) 0.82
Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago. PLoS One (2015) 0.81
A description of the hepatitis B virus genomic background in a high-prevalence area in China. Virol J (2014) 0.81
Molecular virology in transfusion medicine laboratory. Blood Transfus (2012) 0.79
How can the blood transfusion medicine community contribute to public health in tough economic times? J Infect Dis (2012) 0.79
Transfusion transmission of HCV, a long but successful road map to safety. Antivir Ther (2012) 0.78
Genetic Characterization of a Panel of Diverse HIV-1 Isolates at Seven International Sites. PLoS One (2016) 0.77
Variations in DEPDC5 gene and its association with chronic hepatitis C virus infection in Saudi Arabia. BMC Infect Dis (2014) 0.76
Molecular characterization of hepatitis c virus in multi-transfused Colombian patients. Virol J (2012) 0.75
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection. Perm J (2017) 0.75
Aspects on the history of transmission and favor of distribution of viruses by iatrogenic action: perhaps an example of a paradigm of the worldwide spread of HIV. Med Microbiol Immunol (2017) 0.75
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res (2003) 10.50
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (2005) 5.60
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nat Med (2000) 2.99
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 2.76
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Genetic variability in hepatitis B viruses. J Gen Virol (2002) 2.45
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion (2010) 2.39
Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr (2003) 2.21
Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology (2008) 2.14
A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res (2009) 2.06
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology (1998) 1.98
Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther (2004) 1.81
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80
Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med (2011) 1.69
Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci (2001) 1.61
New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion (1998) 1.39
Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS (2003) 1.34
Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries. Clin Infect Dis (2001) 1.28
Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS (2002) 1.27
Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. J Med Virol (2005) 1.24
Worldwide transmission of drug-resistant HIV. AIDS Rev (2003) 1.22
Genotyping Hepatitis B virus from whole- and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J Gen Virol (2006) 1.21
Hepatitis B virus genetic diversity. J Med Virol (2006) 1.21
Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion (2009) 1.19
HIV transmission and primary drug resistance. AIDS Rev (2006) 1.12
Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin Microbiol Infect (2010) 1.09
Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr (2006) 1.08
European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol (2006) 1.08
Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis (2004) 1.07
Infection with HIV type 1 group M non-B subtypes in individuals living in New York City. J Acquir Immune Defic Syndr (2004) 0.95
Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses (2003) 0.94
Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion (2008) 0.93
Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome. J Clin Microbiol (2010) 0.92
Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis (2011) 0.88
Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007. Transfusion (2010) 0.88
HIV infection among U.S. Army and Air Force military personnel: sociodemographic and genotyping analysis. AIDS Res Hum Retroviruses (2010) 0.86
HIV global surveillance: foundation for retroviral discovery and assay development. J Med Virol (2006) 0.85
European collaborative evaluation of the Enzygnost HBsAg 6.0 assay: performance on hepatitis B virus surface antigen variants. J Med Virol (2011) 0.83
Surveillance of HIV-1 genetic subtypesand diversity in the US blood supply. Transfusion (2000) 0.82
Epidemiological aspects of transmitted HIV drug resistance. Scand J Infect Dis Suppl (2003) 0.79
Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: implications for blood safety, diagnostics, treatment, and molecular epidemiology. J Med Virol (2006) 0.78
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med (2010) 5.32
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation (2013) 3.84
Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis (2002) 3.83
Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med (2003) 3.37
Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology (2013) 3.35
A newly identified bocavirus species in human stool. J Infect Dis (2009) 3.25
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS (2002) 3.22
A highly prevalent and genetically diversified Picornaviridae genus in South Asian children. Proc Natl Acad Sci U S A (2008) 3.12
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Virus and antibody dynamics in acute west nile virus infection. J Infect Dis (2008) 2.84
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion (2012) 2.69
Convenience, the bane of our existence, and other barriers to donating. Transfusion (2006) 2.69
Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis (2010) 2.66
A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog (2012) 2.63
The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion (2009) 2.56
Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2011) 2.53
A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion (2005) 2.51
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion (2010) 2.39
Biospecimen repositories: are blood donors willing to participate? Transfusion (2010) 2.33
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med (2005) 2.32
The consequences of temporary deferral on future whole blood donation. Transfusion (2007) 2.31
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion (2008) 2.27
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr (2003) 2.21
Motivations to donate blood: demographic comparisons. Transfusion (2002) 2.20
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
The detection of acute HIV infection. J Infect Dis (2010) 2.14
The safety of the blood supply--time to raise the bar. N Engl J Med (2015) 2.08
Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med (2004) 2.08
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
The impact of male-to-male sexual experience on risk profiles of blood donors. Transfusion (2005) 2.02
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion (2009) 2.00
Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion (2003) 2.00
Rapidly expanding genetic diversity and host range of the Circoviridae viral family and other Rep encoding small circular ssDNA genomes. Virus Res (2011) 1.97
The whole is greater than the sum of its parts: hemostatic profiles of whole blood variants. J Trauma Acute Care Surg (2014) 1.88
Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion (2010) 1.88
The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med (2005) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis (2012) 1.86
Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men. Transfusion (2009) 1.85
Donation archives and prospective donor-recipient repositories: indispensable tools for monitoring blood safety. Transfusion (2007) 1.85
Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil. Transfusion (2005) 1.84
Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses (2006) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog (2009) 1.81
Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa. JAMA (2006) 1.78
West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis (2006) 1.76
Factors influencing donor return. Transfusion (2007) 1.75
Dynamics of viremia in early hepatitis C virus infection. Transfusion (2005) 1.72
Current and emerging infectious risks of blood transfusions. JAMA (2003) 1.72
Attitudes toward blood donation incentives in the United States: implications for donor recruitment. Transfusion (2003) 1.70